Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer

Autor: Matthaiou EI, Barar J, Sandaltzopoulos R, Li C, Coukos G, Omidi Y

Publikováno v: International Journal of Nanomedicine, Vol 2014, Iss Issue 1, Pp 1855-1870 (2014)

Efthymia-Iliana Matthaiou,1,2 Jaleh Barar,1,3 Raphael Sandaltzopoulos,2 Chunsheng Li,1 George Coukos,1,4 Yadollah Omidi1,3 1Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 2Department of

Externí odkaz: https://doaj.org/article/d7d0745d409d41df9f5d87e79f6f85f1

The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial.

Autor: Matthaiou EI; Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, USA., Sharifi H; Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, USA., O'Donnell C; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Chiu W; Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, USA., Owyang C; Department of Medicine, Division of Pulmonary and Critical Care Medicine, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA., Chatterjee P; Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, USA., Turk I; Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, USA., Johnston L; Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA., Brondstetter T; Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA., Morris K; Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, USA., Cheng GS; Clinical Research Division, Section of Pulmonary and Critical Care, Fred Hutchinson Cancer Research Center, Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, WA, USA., Hsu JL; Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, USA. joehsu@stanford.edu.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2022 Aug; Vol. 57 (8), pp. 1319-1326. Date of Electronic Publication: 2022 May 31.

TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.

Autor: Matthaiou EI; Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.; Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece., Guo Y; Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.; University of Shanghai, Shanghai, China., Barar J; Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.; Research Center for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran., Sandaltzopoulos R; Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece., Kandalaft LE; Ludwig Institute for Cancer Research, Lausanne and University of Lausanne, Lausanne, Switzerland., Li C; Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA., Coukos G; Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.; Ludwig Institute for Cancer Research, Lausanne and University of Lausanne, Lausanne, Switzerland., Omidi Y; Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.; Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA.

Publikováno v: BioImpacts : BI [Bioimpacts] 2022; Vol. 12 (1), pp. 65-86. Date of Electronic Publication: 2021 Dec 19.